<?xml version="1.0" encoding="UTF-8"?>
<xml>
 <records>
  <record>
   <ref-type name="Journal Article">17</ref-type>
   <contributors>
    <authors>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
    </authors>
   </contributors>
   <titles>
    <title></title>
   </titles>
   <dates>
    <year>2023</year>
    <pub-dates>
     <date>2023-05-02</date>
    </pub-dates>
   </dates>
   <doi>10.1007/s11094-023-02832-1</doi>
   <abstract>Thietane-containing 4-(2-oxo-2-phenylethyl)-1H-1,2,4-triazol-4-ium bromides were synthesized by&#13;
quaternization of thietanyltriazoles with phenacyl bromides. The starting thietanyltriazoles were obtained by&#13;
the reaction of 1,2,4-triazoles and 2-chloromethylthiirane followed by oxidation of 1-(thietan-3-yl)-1,2,4-triazole to 1-(1-oxidotheitan-3-yl)-1,2,4-triazole and 1-(1,1-dioxidothietan-3-yl)-1,2,4-triazole. The structures&#13;
of the synthesized compounds were confirmed by IR, PMR, and 13C and 15N NMR spectroscopy. An in vivo&#13;
study of the antidepressant activity revealed the promising compound 1-(1,1-dioxidothietan-3-yl)-4-(2-oxo2-phenylethyl)-1H-1,2,4-triazol-4-ium bromide (IXa), which statistically significantly reduced the duration&#13;
of immobilization in the forced swimming test by 44% as compared to the control group. Compound IXa is a&#13;
low-toxic substance (class 4 toxicity) with a high bioavailability predicted according to in silico calculations</abstract>
   <urls>
    <web-urls>
     <url>https://repo.bashgmu.ru/publication/2095</url>
    </web-urls>
    <pdf-urls>
     <url>https://repo.bashgmu.ru/files/2268</url>
    </pdf-urls>
   </urls>
  </record>
 </records>
</xml>
